By modulating pathways such as NF-κB and TGF-β, curcumin reduces hepatic inflammation and fibrosis, making it another potential therapeutic agent in MASLD [26,30]. The gene discussed is NFKB1; the disease is metabolic dysfunction-associated steatotic liver disease.